MET and renal cell carcinoma: In the case of the newly diagnosed RCC possessing a common MET D1028 mutation that confers MET exon 14 skipping74, FDA-approved targeted therapies, including tepotinib and capmatinib, which have demonstrated promising clinical activity in NSCLC, were lost due to the diagnostic update.